Angiogenesis, Exudation and Degeneration Meeting

Healio brings you the highlights from Angiogenesis, Exudation, and Degeneration 2019. Refer back to this page often for the latest news from the meeting, perspectives and interviews with leading researchers and clinicians, and to review archives of past meetings.
Meeting News

OCS-01 shows clinical proof of concept in DME treatment

February 20, 2020
Phase 2 data for OCS-01, a proprietary topical nanoparticle formulation of dexamethasone from Oculis to treat patients with diabetic macular edema…
Meeting News

Phase 1 study of THR-687 for DME shows improvement in vision

February 13, 2020
An open-label, multicenter, single dose escalation study evaluating the safety of a single intravitreal injection of three increasing doses of…
Meeting News

Eylea reduced risk for vision-threatening complications at 2 years

February 12, 2020
The 2-year results of the phase 3 PANORAMA trial evaluating intervention with aflibercept for patients with moderately severe to severe…

Regeneron presents positive data from PANORAMA trial

February 14, 2019
Patients in the PANORAMA trial who underwent early intervention with Eylea experienced improvements in diabetic retinopathy severity, and the…
Meeting News

Smartphones can improve ocular health screening, clinical research

February 23, 2017
MIAMI — Smartphones and mobile devices enabled with retinal fundus photography accessories can help bring ophthalmology screening services to…
Meeting News

'Slurry' Kenalog cost-effective, easy alternative for intraocular steroid delivery

February 22, 2017
MIAMI — A single injection of Kenalog lasts for an average of almost 8.5 months and has average or lower side effects compared with other…
Meeting News

Anti-VEGF therapy may not have impact on cataract surgery outcomes in DME patients

February 21, 2017
MIAMI — Anti-VEGF therapy for the treatment of diabetic macular edema does not have a negative impact on patients who undergo cataract surgery…
Meeting NewsPerspective

Novel protein targets tissue factor involvement in neovascular AMD

February 20, 2017
MIAMI — Best corrected visual acuity outcomes were comparable at 6 months for the combination of ICON-1, a novel protein, plus ranibizumab…
Meeting News

Brolucizumab shows noninferiority to aflibercept for treatment of AMD

February 17, 2017
MIAMI — Two phase 2 studies comparing brolucizumab vs. aflibercept for the treatment of neovascular age-related macular degeneration showed…
Meeting NewsPerspective

OCT angiography may be used to identify biomarkers of neovascular activity

February 16, 2017
MIAMI — Several biomarkers of neovascularization in age-related macular degeneration, such as secondary small vessel branching and greater…